Insights

Why GoodRx Stock Got Hammered Today

What happened
The stock market is in free fall right now, but it’s far worse for shares of prescription-drug discounter GoodRx (NASDAQ: GDRX). The company reported financial results for the first quarter of 2022 after the market closed yesterday.
While Q1 results exceeded management’s guidance, the company’s forward guidance — or lack thereof — sparked major concerns from investors today. As of 11:30 a.m. ET, GoodRx stock is down 28% today, 76% year to date, and 84% from its all-time high in 2021.
So what
As already mentioned, Q1 results weren’t bad. Management had guided for Q1 revenue of $200 million and an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin of 28% to 30%. Q1 revenue of $203 million and an adjusted EBITDA margin of 31.8% surpassed these expectations.
Image source: Getty Images.

However, investing isn’t about the past as much as it’s about the future. And GoodRx’s future is murky. But don’t take my word for it.
In its letter to shareholders, management wrote, “We believe it is unlikely we will be able to achieve the FY [full-year] 2022 guidance we provided on our fourth quarter earnings call,” followed by, “We will not be providing full year expectations at this time.”
Here’s the issue: Towards the end of Q1, an unnamed grocery store made changes and isn’t accepting all drug discounts from companies like GoodRx. Management expects this one change to lower second-quarter revenue by $30 million. And the uncertainty is preventing management from giving guidance for the rest of the year. 
Now what
Prominent analysts downgraded GoodRx stock across the board. Part of this is because the S&P 500 is down 17% as of this writing (a historically large pullback) and professional money managers are more acutely averse to uncertainty than normal. Therefore, by withdrawing guidance at this time, GoodRx was bound to get hammered.
However, that’s not to say the market is necessarily overreacting. Today’s news is a reminder of one of the key risks GoodRx has to overcome if it’s going to be a good long-term investment. In its filings with the Securities and Exchange Commission (SEC), the company talks about how negotiations between pharmacies and pharmacy benefit managers (PBMs) are outside of GoodRx’s control and could impact its business. This is what we’re seeing today.
It’s not over for GoodRx. But the company will need to overcome some real challenges going forward.
Jon Quast has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends GoodRx Holdings, Inc. The Motley Fool has a disclosure policy. –

What happened

The stock market is in free fall right now, but it’s far worse for shares of prescription-drug discounter GoodRx (NASDAQ: GDRX). The company reported financial results for the first quarter of 2022 after the market closed yesterday.

While Q1 results exceeded management’s guidance, the company’s forward guidance — or lack thereof — sparked major concerns from investors today. As of 11:30 a.m. ET, GoodRx stock is down 28% today, 76% year to date, and 84% from its all-time high in 2021.

So what

As already mentioned, Q1 results weren’t bad. Management had guided for Q1 revenue of $200 million and an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin of 28% to 30%. Q1 revenue of $203 million and an adjusted EBITDA margin of 31.8% surpassed these expectations.

Image source: Getty Images.

However, investing isn’t about the past as much as it’s about the future. And GoodRx’s future is murky. But don’t take my word for it.

In its letter to shareholders, management wrote, “We believe it is unlikely we will be able to achieve the FY [full-year] 2022 guidance we provided on our fourth quarter earnings call,” followed by, “We will not be providing full year expectations at this time.”

Here’s the issue: Towards the end of Q1, an unnamed grocery store made changes and isn’t accepting all drug discounts from companies like GoodRx. Management expects this one change to lower second-quarter revenue by $30 million. And the uncertainty is preventing management from giving guidance for the rest of the year. 

Now what

Prominent analysts downgraded GoodRx stock across the board. Part of this is because the S&P 500 is down 17% as of this writing (a historically large pullback) and professional money managers are more acutely averse to uncertainty than normal. Therefore, by withdrawing guidance at this time, GoodRx was bound to get hammered.

However, that’s not to say the market is necessarily overreacting. Today’s news is a reminder of one of the key risks GoodRx has to overcome if it’s going to be a good long-term investment. In its filings with the Securities and Exchange Commission (SEC), the company talks about how negotiations between pharmacies and pharmacy benefit managers (PBMs) are outside of GoodRx’s control and could impact its business. This is what we’re seeing today.

It’s not over for GoodRx. But the company will need to overcome some real challenges going forward.

Jon Quast has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends GoodRx Holdings, Inc. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex Securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here To Get Started
FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here For More Info